Literature DB >> 21726886

Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1).

Julie M Belanger1, Yossef Raviv, Mathias Viard, M Jason de la Cruz, Kunio Nagashima, Robert Blumenthal.   

Abstract

Previously we reported that hydrophobic aryl azides partition into hydrophobic regions of the viral membrane of enveloped viruses and inactivate the virus upon UVA irradiation for 2 min. Prolonged irradiation (15 min) resulted in viral protein aggregation as visualized via Western blot analysis, due to reactive oxygen species (ROS) formation, with preservation of the surface antigenic epitopes. Herein, we demonstrate that these aggregates show detergent resistance and that this property may be useful towards the creation of a novel orthogonal virus inactivation strategy for use in preparing experimental vaccines. When ROS-modified HIV virus preparations were treated with 1% Triton X-100, there was an increase in the percent of viral proteins (gp41, p24) in the viral pellet after ultracentrifugation through sucrose. Transmission electron microscopy (TEM) of these detergent-resistant pellets shows some recognizable virus fragments, and immunoprecipitation studies of the gp41 aggregates suggest the aggregation is covalent in nature, involving short-range interactions. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726886      PMCID: PMC3152596          DOI: 10.1016/j.virol.2011.06.007

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

Review 1.  Inactivated- or killed-virus HIV/AIDS vaccines.

Authors:  Haynes W Sheppard
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

2.  The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.

Authors:  Rebecca Jane Cox; Arnt-Ove Hovden; Karl Albert Brokstad; Ewa Szyszko; Abdullah Sami Madhun; Lars Reinhardt Haaheim
Journal:  Vaccine       Date:  2006-06-05       Impact factor: 3.641

3.  Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.

Authors:  B Poon; J T Safrit; H McClure; C Kitchen; J F Hsu; V Gudeman; C Petropoulos; T Wrin; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Conservation of HIV-1 gp120 neutralizing epitopes after formalin inactivation.

Authors:  Q J Sattentau
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

5.  Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope.

Authors:  Yossef Raviv; Mathias Viard; Julian W Bess; Elena Chertova; Robert Blumenthal
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Oxidation of high-density lipoprotein HDL3 leads to exposure of apo-AI and apo-AII epitopes and to formation of aldehyde protein adducts, and influences binding of oxidized low-density lipoprotein to type I and type III collagen in vitro1.

Authors:  J Greilberger; G Jürgens
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

7.  Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.

Authors:  Yoshio Tano; Hiroyuki Shimizu; Javier Martin; Yorihiro Nishimura; Bunsiti Simizu; Tatsuo Miyamura
Journal:  Vaccine       Date:  2007-08-17       Impact factor: 3.641

8.  Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide.

Authors:  Anuj Sharma; Yossef Raviv; Anu Puri; Mathias Viard; Robert Blumenthal; Radha K Maheshwari
Journal:  Biochem Biophys Res Commun       Date:  2007-04-26       Impact factor: 3.575

9.  Immunogenicity of a viral model vaccine after different inactivation procedures.

Authors:  M F Bachmann; C Bast; H Hengartner; R M Zinkernagel
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

10.  Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; Mathias Viard; Mohamed Aitichou; Xiaoli Chi; Sofi Ibrahim; Robert Blumenthal; Yossef Raviv; Sina Bavari; M Javad Aman
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

View more
  5 in total

1.  Orthogonal inactivation of influenza and the creation of detergent resistant viral aggregates: towards a novel vaccine strategy.

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; Ulrich Baxa; Robert Blumenthal
Journal:  Virol J       Date:  2012-03-26       Impact factor: 4.099

Review 2.  Application of radiation technology in vaccines development.

Authors:  Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

3.  Modification of face masks with zeolite imidazolate framework-8: A tool for hindering the spread of COVID-19 infection.

Authors:  Daria Givirovskaia; Georgy Givirovskiy; Marjo Haapakoski; Sanna Hokkanen; Vesa Ruuskanen; Satu Salo; Varpu Marjomäki; Jero Ahola; Eveliina Repo
Journal:  Microporous Mesoporous Mater       Date:  2022-02-21       Impact factor: 5.455

Review 4.  Nanotechnology: A Potential Weapon to Fight against COVID-19.

Authors:  Atul K Tiwari; Anupa Mishra; Govind Pandey; Munesh K Gupta; Prem C Pandey
Journal:  Part Part Syst Charact       Date:  2021-11-21       Impact factor: 3.467

5.  Inactivation of two SARS-CoV-2 virus surrogates by electron beam irradiation on large yellow croaker slices and their packaging surfaces.

Authors:  Zonghong Luo; Ke Ni; Yuancheng Zhou; Guanhong Chang; Jiangtao Yu; Chunling Zhang; Wenqi Yin; Dishi Chen; Shuwei Li; Shengyao Kuang; Peng Zhang; Kui Li; Junqing Bai; Xin Wang
Journal:  Food Control       Date:  2022-09-06       Impact factor: 6.652

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.